- Home
- GRCE vs FGEN Comparison
GRCE vs FGEN Comparison
Compare GRCE & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- FGEN
- Stock Information
- Founded
- GRCE 2002
- FGEN 1993
- Country
- GRCE United States
- FGEN United States
- Employees
- GRCE N/A
- FGEN N/A
- Industry
- GRCE
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GRCE
- FGEN Health Care
- Exchange
- GRCE NYSE
- FGEN Nasdaq
- Market Cap
- GRCE 30.9M
- FGEN 34.5M
- IPO Year
- GRCE N/A
- FGEN 2014
- Fundamental
- Price
- GRCE $3.24
- FGEN $0.46
- Analyst Decision
- GRCE
- FGEN
- Analyst Count
- GRCE 0
- FGEN 0
- Target Price
- GRCE N/A
- FGEN N/A
- AVG Volume (30 Days)
- GRCE 77.8K
- FGEN 1.2M
- Earning Date
- GRCE 02-14-2025
- FGEN 02-24-2025
- Dividend Yield
- GRCE N/A
- FGEN N/A
- EPS Growth
- GRCE N/A
- FGEN N/A
- EPS
- GRCE N/A
- FGEN N/A
- Revenue
- GRCE N/A
- FGEN $180,015,000.00
- Revenue This Year
- GRCE N/A
- FGEN $21.91
- Revenue Next Year
- GRCE N/A
- FGEN N/A
- P/E Ratio
- GRCE N/A
- FGEN N/A
- Revenue Growth
- GRCE N/A
- FGEN 16.15
- 52 Week Low
- GRCE $2.13
- FGEN $0.18
- 52 Week High
- GRCE $4.97
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- FGEN 41.45
- Support Level
- GRCE N/A
- FGEN $0.45
- Resistance Level
- GRCE N/A
- FGEN $0.51
- Average True Range (ATR)
- GRCE 0.00
- FGEN 0.04
- MACD
- GRCE 0.00
- FGEN -0.01
- Stochastic Oscillator
- GRCE 0.00
- FGEN 3.25
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.